Chengdu Olymvax Biopharmaceuticals Inc. (SHA:688319)

SHA:688319 Revenue

Chengdu Olymvax Biopharmaceuticals had revenue of 87.49M CNY in the quarter ending March 31, 2025, with 23.58% growth. This brings the company's revenue in the last twelve months to 605.55M, up 21.10% year-over-year. In the year 2024, Chengdu Olymvax Biopharmaceuticals had annual revenue of 588.86M with 18.69% growth.

• Revenue (ttm): 605.55M
• Revenue Growth: +21.10%
• P/S Ratio: 11.73
• Revenue / Employee: 1.29M
• Employees: 470
• Market Cap: 7.10B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	588.86M	92.74M	18.69%
Dec 31, 2023	496.12M	-51.36M	-9.38%
Dec 31, 2022	547.48M	60.33M	12.38%
Dec 31, 2021	487.15M	167.04M	52.18%
Dec 31, 2020	320.11M	141.00M	78.72%